

“All of the author’s institutions received funding from Glaxo-Smith-Kline to conduct the original study, published in 2001 in the Journal of the American Academy of Child and Adolescent Psychiatry, entitled, “Efficacy of paroxetine in the treatment of adolescent major depression: a randomized controlled trial.”

---

Drs. Birmaher, Carlson, Clarke, Keller, Ryan and Strober currently have research grant support from the National Institute of Health.

---

Additional disclosures are provided for the past 36 months, and anticipated for the next 12 months, as instructed in the current British Medical Journal (BMJ) guidelines for “competing Interests.” If a longer time duration is desired please notify the corresponding author (Martin Keller) and he will query all authors. The additional disclosures are:

Dr. Carlson has received research support from Pfizer and Glaxo-Smith-Kline.

1. What is the company’s role, meaning whether they had any role in: study design; data collection; access, analysis, or interpretation; writing of the report; or the decision to publish. STONY BROOK WAS A SITE IN THE TWO PROJECTS. THE STUDIES WERE INDUSTRY SPONSORED, FDA REQUESTED TRIALS OVER WHICH THE COMPANY HAD COMPLETE CONTROL. WE MERELY SUPPLIED PATIENTS.
2. How does the interest topic relate to the content of our letter? THE PFIZER STUDY WAS FOR AN ANTIDEPRESSANT; THE GSK STUDY WAS FOR PREVENTION OF A BIPOLAR EPISODE FOR LAMICTAL.
3. Is there a contractual agreement to disseminate product information? THERE IS NO CONTRACT TO DISSEMINATE INFORMATION.
4. Were there any payments to you? NO.
5. Were there any payments to your institution? YES.

Dr. Emslie’s competing interests are detailed in the accompanying/attached table which was emailed separately to Ms. Sharon Davies of BMJ, as per her instructions to me.

Dr. Kutcher- received an honorarium and travel costs to be part of a review committee on a Pfizer supported grant competition about 3 years ago. In addition Dr. Kutcher reports that "I AM PART OF AN INTERNATIONAL ADVISORS GROUP ASSISTING A CAMBRIDGE UNIVERSITY GROUP THAT ARE SCIENTIFIC ADVISORS TO LUNDBECK ON A YOUTH DEPRESSION STUDY THAT WILL USE MEDICATION (VORTIOXETINE AND FLUOXETINE) PLUS A PSYCHOLOGICAL INTERVENTION THAT THE CAMBRIDGE GROUP HAS CREATED. I HAVE NOT HAD ANY ROLE IN THE DESIGN, ANALYSIS PLAN NOR ANY COMPONENT OF

THE STUDY NOR WILL I BE INVOLVED IN THE STUDY APPLICATION, DATA ANALYSIS

NOR ANY OTHER PART OF THE STUDY. I HAVE NO KNOWLEDGE OF ANY OF THE PLANS

OR INTENTS OF LUNDBECK WITH REGARDS TO THIS STUDY OR TO ANY OTHER

ACTIVITIES THE COMPANY IS INVOLVED IN. NONE OF THIS ADVISORY ACTIVITY IS RELATED TO THE LETTER ATTACHED APART FROM THE FACT THAT THE LUNDBECK STUDY IS A STUDY IN YOUTH DEPRESSION THAT USES ANTIDEPRESSANTS AS ONE OF THE TREATMENT MODALITIES."